www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/19760

Title: The Disease Burden of Hepatitis C in Belgium : An update of a realistic disease control strategy
Authors: Stärkel, P.
Vandijck, Dominique
Laleman, W.
Van Damme, P.
Moreno, C.
Blach, S.
Razavi, H.
Van Vlierberghe, H.
Issue Date: 2015
Publisher: UNIV CATHOLIQUE LOUVAIN-UCL
Citation: ACTA GASTRO-ENTEROLOGICA BELGICA, 78 (2), p. 228-232
Abstract: Background : This manuscript serves as an update to position papers published in 2014 based on the available Belgian hepatitis C virus (HCV) epidemiological data. Methods : Building on the current standard of care (2015 : 900 >= F3 patients treated with 70-85% SVR), four new scenarios were developed to achieve the goals of near viral elimination and prevention of HCV associated morbidity and mortality by 2026 and 2031. Increases in treatment efficacy were assumed in 2016 (90% SVR) and 2017 (95% SVR). Results : Scenario 1 : Treating 6,670 patients annually by 2018 (>= F0 beginning in 2017) and diagnosing 3,790 patients annually by 2020, a 90% reduction in viremic cases and advanced outcomes was observed by 2026. Scenario 2 : Treating 4,300 patients annually by 2018 (>= F0 beginning in 2020) without increasing the number diagnosed, a 90% reduction in viremic cases and 85%-95% reduction in advanced outcomes was observed by 2031. Scenario 3 : Treating 5,000 >= F2 patients annually by 2018, and diagnosing 3,620 patients annually by 2020, a 90% reduction in advanced outcomes and 50% reduction in viremic cases was observed by 2026. Scenario 4 : Treating 3,100 >= F2 patients annually by 2018 without increasing the number diagnosed, a 90%-95% reduction in advanced outcomes and 55% reduction in viremic cases was observed by 2031. Conclusions : Scenario 2 would provide the most favorable balance of outcomes (90% reduction in viremic prevalence and advanced outcomes) and realistic requirements for implementation (gradual increase in treatment, delayed incorporation of patients with no/mild fibrosis).
Notes: [Staerkel, P.] UCL, Clin Univ St Luc, Brussels, Belgium. [Vandijck, D.] Univ Ghent, B-9000 Ghent, Belgium. [Vandijck, D.] Hasselt Univ, Dept Hlth Econ & Patient Safety, Diepenbeek, Belgium. [Laleman, W.] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium. [Van Damme, P.] Univ Antwerp, B-2020 Antwerp, Belgium. [Moreno, C.] Univ Libre Bruxelles, Erasme Univ Hosp, Brussels, Belgium. [Blach, S.; Razavi, H.] CDA, Louisville, CO USA. [Van Vlierberghe, H.] Ghent Univ Hosp, Ghent, Belgium.
URI: http://hdl.handle.net/1942/19760
ISI #: 000361654800006
ISSN: 0001-5644
Category: A1
Type: Journal Contribution
Validation: ecoom, 2016
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
N/A491.76 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.